by The global hospital acquired disease testing market for the historical period 2017–2018 and forecast period 2019–2027, Increase in prevalence of hospital acquired infections and rise in the number of drug resistant pathogens and Establishment of government guidelines and code for prevention of hospital acquired infections are projected to drive the global hospital acquired disease testing market during the forecast period
According to the report, the global hospital acquired disease testing market was valued at US$ 798.6 Mn in 2018 and is anticipated to expand at a CAGR of 14.7% from 2019 to 2027
Get the sample copy of report@ https://qyresearchmedical.com/sample/111695
Rise in the Number of Drug Resistant Pathogens: Key Drivers
Rapid and efficient solutions for infection detection not only assist in controlling the incidence of nosocomial infections, but also in controlling the overall medical costs, hospital stays, and death.
Widespread availability of more sophisticated infection detection solutions particularly those under molecular diagnostics and their proven efficiency in delivering faster results has led to rise in demand for such products across the world.
Government initiatives and hospital acquired infection controlling authorities focusing on spreading awareness about hospital acquired infection and available treatments are driving demand for hospital acquired infection testing.
Therefore, increase in prevalence of hospital acquired infections and rise in drug resistant pathogens are fueling the growth of the hospital acquired infection testing market.
Establishment of Government Guidelines and Code for Prevention of hospital acquired infections to Boost Market Growth
According to the U.S. Department of Health and Human Services, hospital acquired infection prevention costs around US$ 28.0 Bn to US$ 33.0 Bn annually. In order to reduce the burden on hospitals resulting from extended stay of patients in hospitals, governments are taking initiatives to reduce hospital acquired infection prevalence in the respective countries.
Developed countries have hospital acquired infection prevention and control authorities, with established guidelines for detection and treatment of hospital acquired infection. For example, the Centers for Disease Control and Prevention (CDC) recommends nucleic acid amplification test for detection of C. difficile, while the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends two-step detection process for identification of C. difficile.
These guidelines drive the market for recommended tests in countries where the regulatory and guiding frameworks are established and followed. Therefore, stringent government regulations would boost the growth of the global hospital acquired infection testing market.
Stringent Regulations and Guidance Framework to Hamper Market
One of the major key constraints for successful adoption of molecular biology based diagnostics involves government regulations. All the major geographical markets have their own form of regulatory regime that covers the diagnostics domain.
Such systems have been created long back and were not designed for the specific intention of regulating molecular biology based diagnostics.
Moreover, the time and capital required to design and develop these products discourage manufacturers to engage in the development of novel and innovative products that could be introduced in various markets. Thus, stringent regulations are likely to restrain market growth during the forecast period.
Global Hospital acquired disease testing Market: Competitive Landscape
This report profiles major players in the global hospital acquired disease testing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.
The hospital acquired disease testing market is highly fragmented with a number of international and local players operating in the market. The companies profiled in the report include
- Abbott Laboratories
- Alere, Inc.,
- Becton
- Dickinson and Company
- bioMérieux SA, F
- Hoffmann-La Roche Ltd
- Hologic, Inc
- Siemens Healthcare
- Diatherix Laboratories, Inc.
- Meridian Bioscience, Inc.,
- Thermo Fisher Scientific, Inc.
Global Hospital acquired disease testing Market: Key Developments
In January 2015, bioMérieux acquired the CEERAM (European Centre for Expertise and Research on Microbial Agents), an innovative molecular virology laboratory that specializes in the detection of foodborne and environmental viruses.
The report on the global hospital acquired disease testing market discussed individual strategies, followed by company profile of manufacturer of hospital acquired disease testing. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hospital acquired disease testing market.
Key Questions Answered in Global Hospital acquired disease testing Market Report
- What is the scope of growth of product companies in the global hospital acquired disease testing market?
- What will be the Y-o-Y growth of the global hospital acquired disease testing market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global hospital acquired disease testing market?
- Will North America continue to be the most profitable market for hospital acquired disease testing providers?
- Which factors are anticipated to hamper the growth of the global hospital acquired disease testing market during the forecast period?
- Which are the leading companies in the global hospital acquired disease testing market?
Global Hospital acquired disease testing Market – Segmentation
Test Type
- Urinary Tract
- Surgical Site
- Pneumonia
- Bloodstream
- MRSA
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111695/2900
